# Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Source: https://onco.cc/trials/nct05239741/  
OnCo record `nct05239741` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab, Oxaliplatin, Bevacizumab and Cetuximab in colorectal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is a phase 3 interventional study registered as NCT05239741 by Merck Sharp & Dohme LLC, with 100 participants enrolled, started 2022-04-02 and due to reach its primary completion in 2028-09-19. Interventions recorded: Pembrolizumab, Oxaliplatin, Leucovorin, 5-fluorouracil, Irinotecan and Bevacizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05239741
- Phase: 3
- Setting: A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05239741: https://clinicaltrials.gov/study/NCT05239741

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05239741.json